USEC announced Test "Station Blackout" American centrifuge program passes

USEC American centrifuge program Announces "Station Blackout" passes Test | BenzingaBenzinga Benzinga Pro Marketfy Facebook Twitter LinkedIn RSS Streaming Google + News free subscription is FreeWhat are you waiting for? Sign up now! Username: Username available!Username taken! Email: Email available!Email taken! Password: leave blank: you already have an account?LoginI user bet that I can't wait to come back here ... Username or email: Password: need an account?Forgot your password? Help Register Login Benzinga-Feed Your Mind. HomeMeglio of BenzingaCareersAboutContact UsPartnersNewsEarningsGuidanceDividendsM ABuybacksLegalManagementRetail SalesOfferingsIPOsInsider TradesBiotech/& FDAMarketsPre-HoursMoversForexCommoditiesOptionsBondsFuturesGlobal EconomicsPreviewsReviewsRatingsAnalyst ColorDowngradesUpgradesInitiationsPrice TargetIdeasLong MarketAfter IdeasShort PressJim CramerRumorsETFsTechStart IdeasTechnicalsFrom UpsSmall-CapTrading-& training strategiesEarningsGuidanceDividendsM ABuybacksLegalManagementRetail SalesOfferingsIPOsInsider TradesBiotech/& FDA market overview keyword TickersArticlesKeywordsSearch ... googlecse Usec American centrifuge program Announces passes "Station Blackout" Test Charles Gross, Benzinga staff writer December 23, 2013 14: 1 + Print follow Email for free Streaming News ticker: USU share:The USEC (NYSE: USU) American centrifuge program in Piketon, Ohio,has successfully passed a test without notice "blackout" which ispart of a program to test the uranium-enrichment technology's techniquereadiness. Technicians, without warning, aborted the external power supplyprovide commercial demonstration cascade structures in order tocheck the availability of equipment, backup systems and personnel atthe uranium enrichment plant to a total loss of external power supply. This testis part of the partnership research, development and demonstrationProgram (RD & D) with the Department of Energy (DOE), designed todemonstrate technical readiness to meet American centrifugenational security needs."I am pleased to report that all our staffSee the full press release-Published In: Contract management news global orientation

Most popular Office Depot, Seattle Genetics and other insiders have been buying Slideshow: No iPhone for China Mobile, iPad demand remains high, and more from the third week of December, China Mobile, Apple iPhone announce on China Mobile 3 g & 4 g networks beginning January 17, 2014 update: Morgan Stanley reiterates on Walgreen company on the following forecast 1QFY14 updated results for clock supplies December 23, 2013 Cowen suggests truth to rumors related articles Allergan (USU) announces American Usec the centrifuge program passes "Blackout" Test Department of energy prepared to extend American centrifuge RD & D program three months morning market losers USEC Noteholder group reaches agreement with financial restructuring plan conditions USEC ships last low enriched uranium cylinders Baltimore Harbour Facility in PaducahKy announces completion of USEC'S American centrifuge RD & D stages all over the Web, we're loving ... Lightspeed Trading Presents: Thunder and Tubleweeds: Trading techniques to the new market Environment Pope Francis Rips ' trickle-down ' economics come see how the Pro trade in this exclusive Webinar, MGM, Wynn Casino Giants vying for u.s. Turf what should you know about AMZN? Partner network get news delivered free Zing talk on Benzinga: Daily Top stories Primer Premarket view more ETF weekly Outlook "weekly Outlook options Daily rating by Charles gross Summary Ackman said his silence was the success in Garnering significant interest in regulatory $HLF in United States and abroad-NY Post Alert option: call CME Group, $ 65; 80,002 Monday vs 20,027 contracts Open Interest. CME Group goes Ex-Dividend on 24 December; Apple acquires BroadMap $83,07 currently, Catch-9to5Mac SFX announces new Marketing Partnership with Anheuser-Busch InBev WidePoint subsidiary iSYS awarded $ 600 M blanket purchase agreement by the Department of Homeland Security more newer 1 reading Office Depot, Seattle Genetics and other insiders have been buying 2 Slideshow: no iPhone for China Mobile, iPad demand remains high, ... 3 China Mobile, Apple iPhone announce on China Mobile 4 g 3 g NET & ... UPDATE 4: Morgan Stanley reiterates on Walgreen company on updated ... 5 Stocks to watch for 6 December 23, 2013 Cowen suggests to 7 voices Allergan iPhone finally arrives to China Mobile 1 DoJ settlement relations with truth related to National City Bank Discrim ... 2 more bad news for Target 3 Micron shares drop following Bank of America Merrill Lynch, Dow ... Jesus wishes 4 shares Tumble after disappointing data showing SFX 5 Announces New Partnership Marketing at Anheuser-Busch InBev 6 analysts: China Mobile deal Apple will add 17 m to 30 m In Increments ... WidePoint subsidiary iSYS 7 awarded $ 600 M purchase blanket Agreeme ... Benzinga Professional subscribe 13:53 Ackman said his silence was the success in Garnering significant interest in regulatory $HLF in United States and abroad-NY Post 13:53 Deere partial sale of landscapes close to PE & co 13:49 option Alert: call CME Group, $ 65; 80,002 Monday vs 20,027 contracts Open Interest. CME Group goes Ex-Dividend on 24 December; Currently $83,07 13:40 DoJ report settlement with National City Bank 13:35 Fitch discrimination-related says Bristol-Myers; Lowers the Outlook to negative 13:32 S P & says may Downgrade Valassis communications 1:27 pm Apple Acquires BroadMap, Catch-13:25 Micron shares drop 9to5Mac following Bank of America's Merrill Lynch Downgrade Jesus wishes 1:24 pm Shares Tumble after disappointing results SFX 13:24 data announces new Marketing Partnership with Anheuser-Busch InBev 1:16 pm WidePoint Subsidiary iSYS awarded the contract for the purchase of $ 600 M covered by Department of Homeland Security 13:15 actions of Steiner Leisure to session highs; Stifel previous analyst suggested buying the Dip 13:12 Charles Gasparino: ' Tweet ackman says regs closing in $HLF is based on discussions w regs believe theyre making it difficult to foresee substantial progress times ' 13:10 S P & Philadelphia updates a + 13: 6 Moody Evol acquisition credit metrics weakens in near term Benzinga says Boulder marks is a fast-growing, media outlet dynamic and innovative financial authorizing investors with high-quality content, unique. Popular BossETFsEconomicsForexHotNewsOptionsPress ChannelsAnalyst RatingsBe your ReleasesStart upsTechTools ProgramBadgesFeedsNews WidgetReal time FeaturesAffiliate & FeedSitemapSubmit TipsAbout BenzingaAbout news UsBlogIn the UsDisclaimerPrivacy and conditions PolicySyndicationTerms NewsCareersContact Benzinga partner 1 (ZING) (877) 440-9464 Benzinga.com © 2013 Cantor Fitzgerald increased PT load ad noting Facebook amplified

Tesaro azioni Tumble dopo dati risultati deludenti

Jesus wishes shares Tumble after disappointing data | BenzingaBenzinga Benzinga Pro Marketfy Facebook Twitter LinkedIn RSS Streaming Google + News free subscription is FreeWhat are you waiting for? Sign up now! Username: Username available!Username taken! Email: Email available!Email taken! Password: leave blank: you already have an account?LoginI user bet that I can't wait to come back here ... Username or email: Password: need an account?Forgot your password? Help Register Login Benzinga-Feed Your Mind. HomeMeglio of BenzingaCareersAboutContact UsPartnersNewsEarningsGuidanceDividendsM ABuybacksLegalManagementRetail SalesOfferingsIPOsInsider TradesBiotech/& FDAMarketsPre-HoursMoversForexCommoditiesOptionsBondsFuturesGlobal EconomicsPreviewsReviewsRatingsAnalyst ColorDowngradesUpgradesInitiationsPrice TargetIdeasLong MarketAfter IdeasShort PressJim CramerRumorsETFsTechStart IdeasTechnicalsFrom UpsSmall-CapTrading-& training strategiesColorDowngradesUpgradesInitiationsPrice Target market analyst overview keyword TickersArticlesKeywordsSearch ... Jesus wishes googlecse shares Tumble after disappointing results data Erika Janowicz, Benzinga staff writer December 23, 2013 13:24 + Follow Print Email free Streaming News ticker: TSRO share:Jesus wishes shares (NASDAQ: TSRO) fell 32.19% to $28,52 as following the announcement that data from two studies have shown that rolapitant for chemotherapy-induced nausea and vomiting (CINV) missed secondary endpoints.BMO Capital Markets analyst Jim Birchenough said that investors were expecting rolapitant of Jesus wishes to differentiate itself from other treatments for CINV based on benefit of nausea that does not reach statistical significance. Birchenough added that a dosing schedule better and the absence of reactions may not be enough to differentiate from Merck Emend.Jesus wishes closed at $37,70 Friday.-Published In: BMO Capital markets Analyst Jim BirchenoughAnalyst color reviews(c) Benzinga.com 2013. Benzinga does not provide investment advice. All rights reserved.Most popular Office Depot, Seattle Genetics and other insiders have been buying Slideshow: No iPhone for China Mobile, iPad demand remains high, and more from the third week of December, China Mobile, Apple iPhone announce on China Mobile 3 G & 4 g networks beginning January 17, 2014 stock watch for December 23, 2013 UPDATE: Morgan Stanley reiterates on Walgreen company updated the following forecast 1QFY14 results Cowen suggests truth of Allergan Rumors related articles (TSRO) Jesus wishes shares Tumble after disappointing results Update Data mid-morning market: markets Surge; Seagate to acquire Xyratex for Rolapitant of $ 374 M morning market losers JESUS WISHES to reach the primary Endpoint in each of two phase 3 studies for the prevention of CINV across the Web, we're loving ... Lightspeed Trading Presents: Thunder and Tubleweeds: Trading techniques to the new market Environment Pope Francis Rips ' trickle-down ' economics come see how the Pro trade in this exclusive Webinar, MGM, Wynn Casino Giants vying for u.s. Turf what should you know about AMZN? Network of partners get Benzinga news delivered free Zing Talk: Daily Top stories Premarket Primer see more» ETF weekly Outlook Outlook options daily weekly reviews by Erika Summary United therapeutic shares Janowicz surge higher after FDA approval of Orenitram, JP Morgan Upgrade Baird Fortinet newly appointed CFO upgrades and revenue catalysts J.P. Morgan initiates coverage on Nasdaq OMX Stifel raises PT Apple following China Mobile support Cowen suggests truth to rumors Allergan more Read more recent Office Depot 1, Seattle Genetics and other insiders have been buying 2 Slideshow: No iPhone for China Mobile, iPad demand remains high, ... 3 China Mobile, Apple iPhone announce on China Mobile 4 g 3 g NET & ... 4 stock UPDATE clock for 5 December 23, 2013: Morgan Stanley reiterates on Walgreen company on updated ... 6 Cowen suggests the truth to 7 voices Allergan iPhone finally arrives to China Mobile 1 analysts: China Mobile deal Apple will add 17 m to 30 m In Increments ... WidePoint subsidiary iSYS assigned 2 $ 600 M purchase blanket Agreeme ... 3 Jos. A banks turn down acquisition offers from men's Wearhouse 4 Corvex, comment on Commonwealth REIT related recent misleading ... 5 ETFS Facebook and Twitter Social Media power (SOCL FB TWTR SELF, GOOG ... 6 Signs pointing to another Santa Claus Rally in 2013 United therapeutic shares soaring 7 over after FDA approval. Benzinga Professional Subscribe WidePoint subsidiary iSYS 13:16 awarded contract for the purchase of $ 600 M covered by Department of Homeland Security 13:15 actions of Steiner Leisure to session highs; Stifel previous analyst suggested buying the Dip 13:12 Charles Gasparino: ' Tweet ackman says regs closing in $HLF is based on discussions w regs believe theyre making it difficult to foresee substantial progress times ' 13:10 S P & updates Philadelphia to says Boulder makes a + 13: 6 Moody Evol acquisition credit metrics Weakens in the short term 13: 2 Hercules Offshore more elevatiPuò spikes be attributed to positive comments to CNBC 13: 0 trust in Read continues as the Senate passes the motion of 2014 budget via ForexLive 12:54 update: IDC 2017 cuts Monitor PC shipment forecast from 110.8 109.6 M M 12:53 unit upgrade: enhanced 2013 IDC Monitor PC shipment forecast from 134.7 M M 12:51 136.3 says Callon consider Lone Star tips 12:50 IDC says worldwide PC Monitor will see positive growth in Q3 13Vede shipments up to 4.5% QoQ 12:49 CMS Reporting deadline for affordable care Act extended to midnight on December 24, 12: 42 adversity Adam Button shows still has some British colonial spirit within via ForexLive & 12:38 pm Gabelli co. Upgrades Stratasys, Inc. to buy DSP Group 12:28 pm Spikes higher; Can be attributed to article Benzinga Globes is a fast growing, dynamic and innovative financial media that empowers investors with high-quality content, unique. Popular BossETFsEconomicsForexHotNewsOptionsPress ChannelsAnalyst RatingsBe your ReleasesStart upsTechTools ProgramBadgesFeedsNews WidgetReal time FeaturesAffiliate & FeedSitemapSubmit TipsAbout BenzingaAbout news UsBlogIn the UsDisclaimerPrivacy and conditions PolicySyndicationTerms NewsCareersContact Benzinga partner 1 (ZING) (877) 440-9464 Benzinga.com © SFX 2013 Announces New Partnership with Anheuser-Busch InBev of Marketing

Cantor Fitzgerald increased PT load ad noting Facebook amplified

Cantor Fitzgerald increased PT amplified announcement noting Facebook | BenzingaBenzinga Benzinga Pro Marketfy Facebook Twitter LinkedIn RSS Streaming Google + News free subscription is FreeWhat are you waiting for? Sign up now! Username: Username available!Username taken! Email: Email available!Email taken! Password: leave blank: you already have an account?LoginI user bet that I can't wait to come back here ... Username or email: Password: need an account?Forgot your password? Help Register Login Benzinga-Feed Your Mind. HomeMeglio of BenzingaCareersAboutContact UsPartnersNewsEarningsGuidanceDividendsM ABuybacksLegalManagementRetail SalesOfferingsIPOsInsider TradesBiotech/& FDAMarketsPre-HoursMoversForexCommoditiesOptionsBondsFuturesGlobal EconomicsPreviewsReviewsRatingsAnalyst ColorDowngradesUpgradesInitiationsPrice TargetIdeasLong MarketAfter IdeasShort PressJim CramerRumorsETFsTechStart IdeasTechnicalsFrom UpsSmall-CapTrading-& training strategiesColorDowngradesUpgradesInitiationsPrice Target market analyst overview keyword TickersArticlesKeywordsSearch ... googlecse Cantor Fitzgerald Facebook increased PT noting amplified load ad Erika Janowicz, Benzinga staff writer December 23, 2013 13:58 + Print follow Email for free Streaming News ticker: FB share:In a report released on Monday, Cantor Fitzgerald analyst Youssef Squali reiterated a buy on Facebook (NASDAQ: FB) and raised the price target from $63,00 to $65,00.Sharks noted that the ad load significantly picked up during the holiday season to about 10% against the approximately 5% reported in the third quarter of 2013. The Analyst commented that this year increases "seems more amplified with bigger brands and a great mix of more expensive click-to-play video ads". Cantor Fitzgerald General announcement generated revenue forecast from $2,106 million to $2,183 million and increased ad revenue from mobile 1.165 million $ to $1,206 million.According to data from comScore Mobile Metrix November, time spent on all mobile devices such as Smartphones and tablet increased 5.2% M/M to 100.7 B minutes and smartphone use increased 46.6% Y/Y to 85.9 B minutes.Facebook has closed at $55,12 Friday. Shares have traded as high as 5.81% to $58,32.-Published In: Cantor Fitzgerald Youssef SqualiAnalyst price Target recurrence color analyst reviews(c) Benzinga.com 2013. Benzinga does not provide investment advice. All rights reserved.Most popular Office Depot, Seattle Genetics and other insiders have been buying Slideshow: No iPhone for China Mobile, iPad demand remains high, and more from the third week of December, China Mobile, Apple iPhone announce on China Mobile 3 g & 4 g networks beginning January 17, 2014 update: Morgan Stanley reiterates on Walgreen company on the following forecast 1QFY14 updated results for clock supplies December 23, 2013 Cowen suggests truth to rumors related articles Allergan (FB) Cantor Fitzgerald increased PT of Facebook ad noting amplified load Facebook and Twitter Social Media power ETF (SOCL, FB, TWTR SELF, GOOG, YNDX) stock watch for December 23, 2013 stock will see A Santa Claus Rally? Segment of the market for 18 December: flat Markets during the first day Post Fed not expect cone to go via Mobile ads all over the Web, we're loving ... Lightspeed Trading Presents: Thunder and Tubleweeds: Trading techniques to the new market Environment Pope Francis Rips ' trickle-down ' economics come see how the Pro trade in this exclusive Webinar, MGM, Wynn Casino Giants vying for u.s. Turf what should you know about AMZN? Network of partners get Benzinga news delivered free Zing Talk: Daily Top stories Premarket Primer see more» ETF weekly Outlook Outlook options daily weekly reviews by Erika Summary United therapeutic shares Janowicz surge higher after FDA approval of Orenitram, JP Morgan Upgrade Baird Fortinet newly appointed CFO upgrades and revenue catalysts J.P. Morgan initiates coverage on Nasdaq OMX Stifel raises PT Apple following China Mobile support Cowen suggests truth to rumors Allergan more Read more recent Office Depot 1, Seattle Genetics and other insiders have been buying 2 Slideshow: No iPhone for China Mobile, iPad demand remains high, ... 3 China Mobile, Apple iPhone announce on China Mobile 4 g 3 g NET & ... UPDATE 4: Morgan Stanley reiterates on Walgreen company on updated ... 5 Stocks to watch for 6 December 23, 2013 Cowen suggests to 7 voices Allergan iPhone finally arrives to China Mobile 1 DoJ settlement relations with truth related to National City Bank Discrim ... 2 more bad news for Target 3 Micron shares drop following Bank of America Merrill Lynch, Dow ... Jesus wishes 4 shares Tumble after disappointing data showing SFX 5 Announces New Partnership Marketing at Anheuser-Busch InBev 6 analysts: China Mobile deal Apple will add 17 m to 30 m In Increments ... WidePoint subsidiary iSYS 7 awarded $ 600 M purchase blanket Agreeme ... Benzinga Professional subscribe 13:53 Ackman said his silence was the success in Garnering significant interest in regulatory $HLF in United States and abroad-NY Post 13:53 Deere partial sale of landscapes close to PE & co 13:49 option Alert: call CME Group, $ 65; 80,002 Monday vs 20,027 contracts Open Interest. CME Group goes Ex-Dividend on 24 December; Currently $83,07 13:40 DoJ report settlement with National City Bank 13:35 Fitch discrimination-related says Bristol-Myers; Lowers the Outlook to negative 13:32 S P & says may Downgrade Valassis communications 1:27 pm Apple Acquires BroadMap, Catch-13:25 Micron shares drop 9to5Mac following Bank of America's Merrill Lynch Downgrade Jesus wishes 1:24 pm Shares Tumble after disappointing results SFX 13:24 data announces new Marketing Partnership with Anheuser-Busch InBev 1:16 pm WidePoint Subsidiary iSYS awarded the contract for the purchase of $ 600 M covered by Department of Homeland Security 13:15 actions of Steiner Leisure to session highs; Stifel previous analyst suggested buying the Dip 13:12 Charles Gasparino: ' Tweet ackman says regs closing in $HLF is based on discussions w regs believe theyre making it difficult to foresee substantial progress times ' 13:10 S P & Philadelphia updates a + 13: 6 Moody Evol acquisition credit metrics weakens in near term Benzinga says Boulder marks is a fast-growing, media outlet dynamic and innovative financial authorizing investors with high-quality content, unique. Popular BossETFsEconomicsForexHotNewsOptionsPress ChannelsAnalyst RatingsBe your ReleasesStart upsTechTools ProgramBadgesFeedsNews WidgetReal time FeaturesAffiliate & FeedSitemapSubmit TipsAbout BenzingaAbout news UsBlogIn the UsDisclaimerPrivacy and conditions PolicySyndicationTerms NewsCareersContact Benzinga partner 1 (ZING) (877) 440-9464 Benzinga.com © 2013 Kerrisdale capital issues letter to Lindsay Board, management

Kerrisdale capital gives the letter to the Council of Lindsay, management

Kerrisdale Capital Management has released the following Monday, December 23 letter to management, Board members and other stakeholders of Lindsay Corporation (NYSE: LNN):Dear Mr. Parod, Mr Christodolou, other members of the Board and stakeholders of Lindsay Lindsay Corporation,On October 25, 2013, we published a letter ("October 25 Letter") for the directors and the members of the Board of Directors ("Board") of Lindsay Corporation ("Lindsay") with a variety of thoughts on how the management and the Board could continue to create shareholder value for equity owners of Lindsay.In response to our letter, Mr Parod and Lindsay paintings engaged in a dialogue with us about our ideas and concerns. Through face-to-face discussions, and communications via email and by phone, we discussed further ways in which the directors and management can continue to maximize the value gained long-term shareholders.In particular, we discussed in our letter of October 25 the company's cash balance now exceeds 15% of the market capitalization of the company, and given that this money will earn a significant return on equity, we have urged the Administration to consider using that money in a most productive way.Through subsequent discussions with the management,See the full press release-Published In: News global management contracts

DoJ Reports Settlement with National City Bank Related to Discrimination

 Il dipartimento di giustizia e l'ufficio di protezione finanziaria dei consumatori ha presentato oggi un ordine di consenso per risolvere le accuse che National City Bank impegnato in un pattern o la pratica della discriminazione che ha aumentato i prezzi di prestito per afro-americani e ispanici debitori che hanno ottenuto mutui residenziali tra il 2002 e il 2008 da uffici di vendita al dettaglio di National City Bank e la rete nazionale di mediatori di ipoteca.L'insediamento, che è soggetta all'approvazione della Corte, è stata depositata in concomitanza con denuncia delle agenzie in US District Court per il distretto occidentale della Pennsylvania. La denuncia sostiene che la National City Bank ha violato la legge giusta di Housing e il pari credito opportunità Act (ECOA) facendo pagare più di 75.000 mutuatari afro-americani e ispanici prezzi più elevati del prestito non si basa sul rischio del mutuatario, ma a causa della loro razza o l'origine nazionale. In particolare, le accuse riguardano prestiti fatti ai mutuatari afro-americani e ispanici attraverso più di 400 uffici retail gestiti direttamente dalla National City Bank a livello nazionale tra il 2002 e il 2008. Le accuse coinvolgono anche prestiti fatti ai mutuatari afro-americani e ispanici tra il 2003 e il 2008 attraverso la rete nazionale di National City Bank di mediatori di ipoteca. National City Bank, che era acquartierato a Cleveland, Ohio, fu acquistata nel 2009 da Pittsburgh-based PNC Financial Services Group, che è il successore nell'interesse National City Bank."Questo insediamento fornirà meritato sollievo a migliaia di mutuatari afro-americani e ispanici che subirono discriminazioni per mano di National City Bank," ha detto il procuratore generale Eric Holder. "Come si sostiene, la banca paga mutuatari tassi più alti non basato sulla loro solvibilità, ma basato sulla loro razza e origine nazionale. Questo presunto condotta ha provocato i prezzi aumentati di prestito per i mutuatari di minoranza. Questo caso segna il passo più recente del dipartimento di giustizia per proteggere gli americani da pratiche discriminatorie di prestito e Mostra che sempre lotteremo per tenere conto di quelli che approfittano dei consumatori per guadagno finanziario.""Con l'insediamento di oggi, migliaia di mutuatari afro-americani e ispanici che sono stati discriminati dalla National City Bank avrà diritto al risarcimento," ha detto recitazione assistente procuratore generale Jocelyn Samuels per divisione di diritti civili del dipartimento di giustizia. "Guardiamo avanti per ulteriore collaborazione con l'ufficio di presidenza nel proteggere i consumatori da illegale e prestito pratiche discriminatorie"."Mutuatari non dovrebbero mai dover pagare di più per un mutuo a causa della loro razza o l'origine nazionale," ha detto il Consumer Financial Protection Bureau direttore Richard Cordray. "Misure di esecuzione di oggi mette i soldi indietro nelle tasche dei consumatori danneggiati e rende chiaro che terremo finanziatori responsabile per gli effetti delle loro pratiche discriminatorie"."Mina fiducia nel nostro sistema bancario quando persone ottenere diverse offerte non solo basate sul loro punteggi di credito, ma il loro colore della pelle," ha detto il procuratore degli Stati Uniti per il distretto settentrionale della Ohio Steve Dettelbach. "Con tutte le cose positive per cui National City Bank si trovava per così tanti anni, questo è un epilogo inquietante di essere entrato da altro lato della contabilità generale. Si spera, insediamento di oggi permettersi qualche sollievo ai clienti che sono stati shortchanged da questo comportamento.""Il nostro impegno per assicurare un trattamento equo e uguale ai sensi della legge è assoluta, ha detto David J. Hickton, procuratore degli Stati Uniti per il distretto occidentale della Pennsylvania. "Questo insediamento affronta un guasto grave di National City per proteggere i potenziali acquirenti di case da pratiche discriminatorie di prestito".Pratiche commerciali di National City Bank ha permesso a suoi ufficiali di prestito e mortgage broker discrezione per variare un prestito tasso di interesse e commissioni dal prezzo che ha regolato basato su elementi oggettivi, legati al credito del mutuatario. Questa discrezione soggettiva e non dei prezzi ha provocato i mutuatari afro-americani e ispanici, pagando più di mutuatari Analogamente qualificato bianco non ispanica.Le accuse nella denuncia riguardano esclusivamente prestiti originati dalla National City Bank e non si riferiscono a qualsiasi mutuo prestito pratiche del PNC Financial Services Group.Secondo i termini dell'insediamento proposto, PNC pagherà $ 35 milioni dollari in un fondo a favore di vittime di discriminazione sulle ipoteche di National City Bank. La soluzione proposta prevede un amministratore indipendente di contattare ed erogare i pagamenti ai mutuatari quale delle agenzie identificano come vittime di discriminazione di National City Bank, senza alcun costo per i mutuatari. PNC pagherà tutti i costi e le spese dell'amministratore. I mutuatari che sono indennizzabili saranno contattati dall'amministratore. Il dipartimento sarà fare un annuncio pubblico e inviare informazioni di contatto sul suo sito Web una volta l'amministratore inizia a contattare le vittime. Gli individui che credono che potrebbero essere stati vittime di discriminazione di National City Bank di prestito e avere domande riguardo l'insediamento possono inviare e-mail al dipartimento di nationalcitybank@usdoj.gov.-Pubblicato In: Notizie legali(c) Benzinga.com 2013. Benzinga non fornisce consulenza per gli investimenti. Tutti i diritti riservati.

Macy confronts another cause of discrimination

In a case of discrimination filed Friday, an African-American shopper told Macy's (NYSE: M) security staff stopped him after he bought a Louis Vuitton bag $ 2,400 and an alarm went off as he tried to close the store.According to club Organizer, Halim Sharif was arrested and searched his bag, as well as a half-dozen white customers left the store without being arrested. Sharif said leave those customers also set off alarms at the 34th Street store.Sharif said he was the only person stopped and had the phone audio and video to prove his claim.The incident happened at Macy's flagship store on historic April 19, 2013.Sharif told the New York Daily News, "it was as clear as black and white. There was no gray area. I've seen people get out before me and after me — and none of them resembled me. Lacked pigmentation. "The 37-year-old promoter who has indicated that he has been sued for unspecified damages Macy, said he decided to speak out after reading the accounts of four alleged instances of racial profiling at Macy and another privately owned retailer Barney's New York.Brooklyn resident, Kayla Phillips, who alleged that he was racially profiled at Barney's in February, also filed a discrimination lawsuit Friday in Brooklyn Supreme Court, according to the Daily News.Macy 's, through a representative, said the company was looking for allegation of Sharif, but want to have no comment because the litigation was pending.According to the representative, "Macy has a zero tolerance for discrimination of any kind. If Macy's generals were not defended, we will take swift and immediate action. "The two stores named in said NYPD officers were the culprits in previous accidents, black shopping bags, including Phillips, Christian Trayon, Rob Brown and Art Palmer of targeting.The NYPD said his officers were simply acting on information provided by the employees of the shop.Meanwhile, Macy was among several retailers that have signed a customer bill of rights ' at the beginning of December. Civil rights leaders, including the Rev. Al Sharpton, met with representatives of local draft the document, which is to be published on the websites of participating stock.In addition to Macy, other signatories include Barneys New York, Macy's and Bloomingdale's property subsidiary of Hudson's Bay Company, Lord & Taylor and Saks Fifth Avenue.At the time of this writing, Jim Probasco had no positions in any securities mentioned.Posted In: lawsuit of African-American Art 34th Street Palmer Barney New York Bloomingdales Brooklyn Brooklyn Supreme Court Halim Sharif of Hudson Bay Company Kayla Phillips Lord & daily news of Taylor Louis Vuitton Macy new york NYPD Rev Al Sharpton Rob Brown Saks Fifth Avenue Trayon legal ChristianNews Media best of Benzinga(c) Benzinga.com 2013. Benzinga does not provide investment advice. All rights reserved.

Micron shares drop following Bank of America Merrill Lynch Downgrade

Micron shares drop following Bank of America Merrill Lynch Downgrade | BenzingaBenzinga Benzinga Pro Marketfy Facebook Twitter LinkedIn RSS Streaming Google + News free subscription is FreeWhat are you waiting for? Sign up now! Username: Username available!Username taken! Email: Email available!Email taken! Password: leave blank: you already have an account?LoginI user bet that I can't wait to come back here ... Username or email: Password: need an account?Forgot your password? Help Register Login Benzinga-Feed Your Mind. HomeMeglio of BenzingaCareersAboutContact UsPartnersNewsEarningsGuidanceDividendsM ABuybacksLegalManagementRetail SalesOfferingsIPOsInsider TradesBiotech/& FDAMarketsPre-HoursMoversForexCommoditiesOptionsBondsFuturesGlobal EconomicsPreviewsReviewsRatingsAnalyst ColorDowngradesUpgradesInitiationsPrice TargetIdeasLong MarketAfter IdeasShort PressJim CramerRumorsETFsTechStart IdeasTechnicalsFrom UpsSmall-CapTrading-& training strategiesColorDowngradesUpgradesInitiationsPrice Target market analyst overview keyword TickersArticlesKeywordsSearch ... googlecse Micron shares Drop following Bank of America Merrill Lynch Downgrade Erika Janowicz, Benzinga staff writer December 23, 2013 13:25 + Follow Print Email free Streaming News ticker: MU share:Shares of Micron Technology (NASDAQ: MU) fall as 4.48% decrease to $21,22 after downgrade from Bank of America Merrill Lynch from neutral to Underperform and $ 1 price target to $19,50.An analyst at Bank of America Merrill Lynch Simon Dong-Woo said that he expects the performance picture microns to weaken and noted that the company is now one of stocks ' less preferred "memory. The analyst wrote on the growing competitive threat from Hynix SK after reports of new factory construction and expects the DRAM spot price to fall on increasing supply.Micron Technology closed at $22,17 Friday.-Published In: Bank of America Merrill Downgrades Target price LynchAnalyst color analyst reviews(c) Benzinga.com 2013. Benzinga does not provide investment advice. All rights reserved.Most popular Office Depot, Seattle Genetics and other insiders have been buying Slideshow: No iPhone for China Mobile, iPad demand remains high, and more from the third week of December, China Mobile, Apple iPhone announce on China Mobile 3 G & 4 g networks beginning January 17, 2014 stock watch for December 23, 2013 UPDATE: Morgan Stanley reiterates on Walgreen company updated the following forecast 1QFY14 results Cowen suggests truth of Allergan Rumors related articles (MU) Micron shares drop following mid-morning update BofAML Downgrade market: markets Surge; Seagate to acquire Xyratex for Top #PreMarket losers U.S. stock futures rise higher Benzinga's downgrade $ 374 M Benzinga ahead of Consumer Sentiment data merchants continue to sell Micron shares despite most Sell-Side defense all over the Web, we're loving ... Lightspeed Trading Presents: Thunder and Tubleweeds: Trading techniques to the new market Environment Pope Francis Rips ' trickle-down ' economics come see how the Pro trade in this exclusive Webinar, MGM, Wynn Casino Giants vying for u.s. Turf what should you know about AMZN? Network of partners get Benzinga news delivered free Zing Talk: Daily Top stories Premarket Primer see more» ETF weekly Outlook Outlook options daily weekly reviews by Erika Summary United therapeutic shares Janowicz surge higher after FDA approval of Orenitram, JP Morgan Upgrade Baird Fortinet newly appointed CFO upgrades and revenue catalysts J.P. Morgan initiates coverage on Nasdaq OMX Stifel raises PT Apple following China Mobile support Cowen suggests truth to rumors Allergan more Read more recent Office Depot 1, Seattle Genetics and other insiders have been buying 2 Slideshow: No iPhone for China Mobile, iPad demand remains high, ... 3 China Mobile, Apple iPhone announce on China Mobile 4 g 3 g NET & ... 4 stock UPDATE clock for 5 December 23, 2013: Morgan Stanley reiterates on Walgreen company on updated ... 6 Cowen suggests the truth to 7 voices Allergan iPhone finally arrives to China Mobile 1 analysts: China Mobile deal Apple will add 17 m to 30 m In Increments ... WidePoint subsidiary iSYS assigned 2 $ 600 M purchase blanket Agreeme ... 3 Jos. A banks turn down acquisition offers from men's Wearhouse 4 Corvex, comment on Commonwealth REIT related recent misleading ... 5 ETFS Facebook and Twitter Social Media power (SOCL FB TWTR SELF, GOOG ... 6 Signs pointing to another Santa Claus Rally in 2013 United therapeutic shares soaring 7 over after FDA approval. Benzinga Professional Subscribe WidePoint subsidiary iSYS 13:16 awarded contract for the purchase of $ 600 M covered by Department of Homeland Security 13:15 actions of Steiner Leisure to session highs; Stifel previous analyst suggested buying the Dip 13:12 Charles Gasparino: ' Tweet ackman says regs closing in $HLF is based on discussions w regs believe theyre making it difficult to foresee substantial progress times ' 13:10 S P & updates Philadelphia to says Boulder makes a + 13: 6 Moody Evol acquisition credit metrics Weakens in the short term 13: 2 Hercules Offshore more elevatiPuò spikes be attributed to positive comments to CNBC 13: 0 trust in Read continues as the Senate passes the motion of 2014 budget via ForexLive 12:54 update: IDC 2017 cuts Monitor PC shipment forecast from 110.8 109.6 M M 12:53 unit upgrade: enhanced 2013 IDC Monitor PC shipment forecast from 134.7 M M 12:51 136.3 says Callon consider Lone Star tips 12:50 IDC says worldwide PC Monitor will see positive growth in Q3 13Vede shipments up to 4.5% QoQ 12:49 CMS Reporting deadline for affordable care Act extended to midnight on December 24, 12: 42 adversity Adam Button shows still has some British colonial spirit within via ForexLive & 12:38 pm Gabelli co. Upgrades Stratasys, Inc. to buy DSP Group 12:28 pm Spikes higher; Can be attributed to article Benzinga Globes is a fast growing, dynamic and innovative financial media that empowers investors with high-quality content, unique. Popular ChannelsAnalyst RatingsBe your ReleasesStart upsTechTools BossETFsEconomicsForexHotNewsOptionsPress ProgramBadgesFeedsNews WidgetReal time FeaturesAffiliate & FeedSitemapSubmit TipsAbout BenzingaAbout news UsBlogIn the UsDisclaimerPrivacy and conditions PolicySyndicationTerms NewsCareersContact Benzinga partner 1 (ZING) (877) 440-9464 Benzinga.com © Jesus wishes shares Tumble after 2013 given disappointing results

More bad news for destination

How big are to target (NYSE: TGT) problems?Investors have bid down stocks only about 1.3 percent Monday, and only about three percent since the news, but that might be the least of her worries.The bad news is piling up for the retailer.First, affected customers of the breach were given the gift added by JPMorgan Chase of spending caps. As a result of the data breach, the Bank allowed customers to withdraw up to $ 100 by ATMs and debit card purchases of $ 300 per day. Customers found out about these limits on Saturday.Some — very, customers criticized the move as without warning and an overreaction.Some customers have complained that the paper was rejected before they received the email about the restrictions. While Chase was the "target" of criticism, destination still bears the brunt of the wrath.Destination has done what any company should do when customers filled his Facebook page with scathing comments; It published an apology and offered a discount of 10% on all purchases this weekend in a bid to keep customers from going elsewhere for their holiday shopping. Apparently, that didn't work the way executives expected goal.The number of transactions was down 3:57 percent over the weekend, according to reports.Reading: Destination data breach could affect 40 million customersBut now the lawsuits.There are reports of lawsuits already filed in California and Oregon against Target alleging that the shop, "failed to implement and maintain reasonable security procedures"In San Francisco, law firm hopes to do in the event a class action.Robert Ahdoot attorney said, "since we have listed every day through the weekend, we are receiving calls from individuals across the country – both unauthorized withdrawals did not by their debt cards or they had authorized use of their credit card. Most say they've never had this problem before. "So far, investors do not seem alarmed by a data breach that could involve more than 40 million customers and be among the biggest in history. Starting from midday trading Monday, the stock is off its lows and analysts have not issued the downgrade of the stock based on the news.Disclosure: at the time of this writing, Tim Parker had no position in above stock.-Published In: JPMorgan Chase legal events TargetNews best of Benzinga(c) Benzinga.com 2013. Benzinga does not provide investment advice. All rights reserved.

SodaStream vs. Keurig: which is the best investment?

Who would have thought that the 2013 would like to see such a disclosure of a variety of House beverage options? In particular, the Americans showed they were ready to take the means of production of the drink out of the hands of bigwigs, such as Coca Cola and Starbucks and take matters into their own hands.The two companies were ready for the market, Sodastream international (NASDAQ: SODA) – which focuses on domestic production of soda and Keurig – which has a coffee house offering production. Both have worked to bring the quality of the beverages served in restaurants and shops.SodaStream is having a nice year. The company's primary offering is a machine and the process by which consumers can make their own carbonated drinks in their homes. Not only selling the machine required for soda water, also sell flavorings.The stock started out about $46,12 2013 before soaring over $76,00 in June. Those who sold at the top were no doubt counting their lucky star, as the stock quickly sold in July and hit a bottom below $ 58. Since then, the stock has traded mostly in the range of $ 54-$ 65, with lots of ups and downs in the process. Stock now sits at just under $ 55 per share.2013 has not been a good year for investors to SodaStream who suffer from high blood pressure.Related: Verizon vs AT&T: which is the best investment?Keurig is a subsidiary of Green Mountain Coffee Roasters (NASDAQ: GMCR) that is having a very respectable year with regard to the stock price. The stock began the year just above $42,00. After a fairly steady climb the stock is topped at less than $89,00 in August. Investors who hold the stock earlier this year and sold near the Summit would have more than doubled their money.It would be a good idea to sell, as the stock is heavily retreat and reached a low in November of just $58,18. For those who resisted the fall in prices, would pay their patience. After showing that his single cup coffee brewing system, K-Cup, was just what they wanted consumers, the stock rebounded well and is now trading over $75,00 per share.In many ways, comparing these two companies is a bit like comparing apples and oranges. Green Mountain has a market capitalization larger than SodaStream and has a much more diverse range of products. But hot new product of Green Mountain, K-Cup, is in direct competition with single soda-bottle on SodaStream machines.Both sell aromas and concentrate on the convenience of being able to produce small amounts of your favorite drink in your home. Although both had its ups and downs this year, Green Mountain seems to have found its footing, while SodaStream is still struggling to find its way.-Published In: Keurig K-cup of Coca-Cola General StarbucksMarkets best of Benzinga(c) Benzinga.com 2013. Benzinga does not provide investment advice. All rights reserved.

SFX Announces New Marketing Partnership with Anheuser-Busch InBev

 SFX Announces New Marketing Partnership with Anheuser-Busch InBev | Benzinga Benzinga Benzinga Pro Marketfy Facebook Twitter LinkedIn Google+ RSS Free Streaming News Membership is FreeWhat are you waiting for? Sign up now! Username: Username available!Username taken! Email: Email available!Email taken! Password: Leave blank: already have an account?User LoginI bet you can't wait to get back in here... Username or email: Password: need an account?Forgot password? Contribute Login Sign up Benzinga - Feed Your Mind. HomeBest of BenzingaCareersAboutContact UsPartnersNewsEarningsGuidanceDividendsM&ABuybacksLegalManagementRetail SalesOfferingsIPOsInsider TradesBiotech/FDAMarketsPre-MarketAfter HoursMoversForexCommoditiesOptionsBondsFuturesGlobal EconomicsPreviewsReviewsRatingsAnalyst ColorDowngradesUpgradesInitiationsPrice TargetIdeasLong IdeasShort IdeasTechnicalsFrom The PressJim CramerRumorsETFsTechStart-UpsSmall-CapTrading Strategies & Education EarningsGuidanceDividendsM&ABuybacksLegalManagementRetail SalesOfferingsIPOsInsider TradesBiotech/FDA Market Overview TickersArticlesKeywordsSearch by keyword...googlecse SFX Announces New Marketing Partnership with Anheuser-Busch InBev Charles Gross, Benzinga Staff Writer December 23, 2013 1:24 PM + Follow Print Email Free Streaming News Tickers: BUD, SFXE Share: SFX Entertainment (NASDAQ: SFXE) announced today thatthey have entered into a global marketing partnership withAnheuser-Busch InBev (Euronext: ABI; NYSE: BUD), the leading globalbrewer and one of the world's top five consumer products companies, thatwill capitalize on the experience and power of both companies and willencompass several ground breaking ideas. Details of the partnership willunfold throughout 2014.See full press releasePosted-In: News Contracts Management Global  Most Popular Office Depot, Seattle Genetics And Others Insiders Have Been Buying Slideshow: No iPhone For China Mobile, iPad Demand Remains High, And More From The Third Week Of December China Mobile, Apple Announce iPhone on China Mobile's 4G & 3G Networks Beginning January 17, 2014 Stocks To Watch For December 23, 2013 UPDATE: Morgan Stanley Reiterates on Walgreen Company on Updated Forecasts Following 1QFY14 Results Cowen Suggests Truth to Allergan Rumors Related Articles (BUD + SFXE) SFX Announces New Marketing Partnership with Anheuser-Busch InBev SFX to Acquire B2S for $14.3M in Cash, 400K Shares of SFX Stock Slideshow: The Top 10 'Highs & Dives' Of S&P 500 Stocks In 2013 Top 4 NYSE Stocks In The Beverages-Brewers Industry With The Highest ROE Top 4 NYSE Stocks In The Beverages-Brewers Industry With The Highest EPS Estimates The Art of Trading Responsibly With BEAM Around the Web, We're Loving... Lightspeed Trading Presents: Thunder and Tubleweeds: Trading Techniques for the New Market Enviroment Pope Francis Rips 'Trickle-Down' Economics Come See How the Pro's Trade in this Exclusive Webinar Wynn, MGM, Other Casino Giants Vying For U.S. Turf What Should You Know About AMZN? Partner Network Get Benzinga's News Delivered Free Zing Talk: Daily Top Stories PreMarket Primer See More » Weekly ETF Outlook Weekly Options Outlook Daily Ratings Summary Posts by Charles Gross DSP Group Spikes Higher; May be Attributed to Globes Article Corvex, Related Comment On Commonwealth REIT's Recent Misleading Actions SEC Files New Insider Trading Lawsuit Involving Onyx Pharmaceuticals -Reuters Option Alert: MGM March $19 Put / $22 Call Straddle; 15,000 Straddle Trade; Currently $22.86 Option Alert: Masco January $23 Call; 2,187 Contract Trade at Ask @$0.45; Currently $22.18 Most Read Most Recent 1 Office Depot, Seattle Genetics And Others Insiders Have Been Buying 2 Slideshow: No iPhone For China Mobile, iPad Demand Remains High,... 3 China Mobile, Apple Announce iPhone on China Mobile's 4G & 3G Net... 4 Stocks To Watch For December 23, 2013 5 UPDATE: Morgan Stanley Reiterates on Walgreen Company on Updated... 6 Cowen Suggests Truth to Allergan Rumors 7 iPhone Finally Comes To China Mobile 1 Analysts: Apple's China Mobile Deal Will Add 17M To 30M In Increm... 2 WidePoint Subsidiary iSYS Awarded $600M Blanket Purchase Agreeme... 3 Jos. A Banks Turns Down Acquisition Offer from Men's Wearhouse 4 Corvex, Related Comment On Commonwealth REIT's Recent Misleading... 5 Facebook and Twitter Power Social Media ETF (SOCL, FB, TWTR, GOOG... 6 Signs Pointing Toward Another Santa Claus Rally In 2013 7 United Therapeutic Shares Rocketing Higher Following FDA Approval... Benzinga Professional Subscribe 01:16 PM WidePoint Subsidiary iSYS Awarded $600M Blanket Purchase Agreement by the Department of Homeland Security 1:15 PM Shares of Steiner Leisure at Session Highs; Stifel Analyst Earlier Suggested Buying the Dip 1:12 PM Charles Gasparino Tweet: ' ackman says regs closing in on $HLF 'Based on discussions w regs we believe theyre making substantial progress difficult to predict timing' 1:10 PM S&P Upgrades Philadelphia to A+ 1:06 PM Moody's Says Boulder Brands' Acquisition Of Evol Weakens Credit Metrics In Near Term 1:02 PM Hercules Offshore Spikes Higher, May be Attributed to Positive CNBC Comments 1:00 PM The confidence in Letta continues as Senate passes 2014 budget motion via ForexLive 12:54 PM UPDATE: IDC Cuts 2017 PC Monitor Shipment Forecast from 110.8M to 109.6M Units 12:53 PM UPDATE: IDC Boosted 2013 PC Monitor Shipment Forecast from 134.7M to 136.3M 12:51 PM Callon Says Will Consider Lone Star Suggestions 12:50 PM IDC Says Worldwide PC Monitor Market Will See Positive Growth in Q3'13, Sees Shipments Up 4.5% QoQ 12:49 PM CMS Reporting Deadline for Affordable Care Act Extended to Midnight Dec. 24th 12:42 PM In the face of adversity Adam Button still shows he has some colonial British spirit within via ForexLive 12:38 PM Gabelli & Co. Upgrades Stratasys, Inc. to Buy 12:28 PM DSP Group Spikes Higher; May be Attributed to Globes Article Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content. Popular ChannelsAnalyst RatingsBe Your Own BossETFsEconomicsForexHotNewsOptionsPress ReleasesStart-upsTechTools & FeaturesAffiliate ProgramBadgesFeedsNews WidgetReal Time FeedSitemapSubmit News TipsAbout BenzingaAbout UsBlogIn the NewsCareersContact UsDisclaimerPrivacy PolicySyndicationTerms and Conditions Benzinga Partners 1 (877) 440-9464 (ZING) Benzinga.com © 2013 Tesaro Shares Tumble After Disappointing Data Results Analysts: Apple's China Mobile Deal Will Add 17M To 30M In Incremental iPhone Sales

Market Wrap For December 13: Major Indices Finish The Day Flat

   Major indices were looking for a rebound after a four day skid which included multiple triple digit point losses for the Dow.Futures pointed to a higher opening as investors found reason to be positive in the House's passing of the budget agreement last night. The markets were unable to hold on to gains throughout the day and ended mostly flat.Investors will certainly have their plates full next week with the U.S. Senate set to vote and finalize the new budget deal. The Federal Reserve will convene on Tuesday and Wednesday as investors will anxiously await the central bank's decision on when it will began to scale back its stimulus measures.The Dow gained 0.10 percent, closing at 15,755.36.The S&P 500 lost 0.01 percent, closing at 1,775.32.The Nasdaq gained 0.06 percent, closing at 4,000.98.Gold gained 0.99 percent, trading at $1,237.00Oil gained 0.04 percent, trading at $91.51 a barrel.Silver gained 1.14 percent, trading at $19.67 an ounce.News of NoteLast night the U.S House overwhelmingly passed a two year budget deal that removes the threat of a shutdown. The deal is making its way to a Democratic Senate and is expected to sing off as early as next week.November Producer Price Index declined 0.1 percent, in line with expectations. October's reading was a decline of 0.2 percent. Core PPI rose 0.1 percent, in line with expectations and lower than the previous reading of 0.2 percent.Goldman Sachs chief currency strategist issued a bold statement on the greenback. “The dollar will weaken through 2014, reaching $1.40 per euro for the first time since October 2011,” Thomas Stolper said. “Tapering is in the price already, we find it difficult to see where the dollar strength would come from,” the analyst added.India's CPI rose 11.2 percent in November, above the 10 percent consensus. The country's central bank is set to meet next week to further tackle the country's inflation worries and weak growth.Japanese industrial production rose one percent in October, slightly lower than the 1.3 percent rise in September.Equities-Specific News of NoteAmazon.com, Inc. (NASDAQ: AMZN) has been upgraded to Strong Buy from Buy at ISI Group with a $430 price target. The analysts believe that a positive holiday shopping performance and growth of Prime members will yield faster revenue margin growth. Shares gained 0.78 percent, closing at $384.24.Related: Amazon To Take On Wholesale Retailers With New Pantry BusinessAnalysts at ISI Group upgraded Bed Bath & Beyond Inc. (NASDAQ: BBBY) to Neutral from Cautious with a revised price target of $75.00, up from a previous $67.00. The analyst noted that sales in the home furnishing category has shown some strength as of late. Shares finished flat for the day at $76.52.Analysts at Raymond James upgraded FedEx Corporation (NYSE: FDX) to Strong Buy from Outperform with a $190 price target. The analyst noted the company's aggressive cost improvement plan will transform the company's earnings power over several years from now. Shares gained 1.15 percent, closing at $137.91.Analysts at Stephens initiated coverage on 3D printer Stratasys Ltd. (NASDAQ: SSYS) with an Overweight rating. Shares gained 0.43 percent, closing at $120.02.3D Systems Corp (NYSE: DDD) acquired Village Plastics, a maker of filaments for a variety of 3D printing materials. Acquisitions have played a key part in 3D Systems Corp growth path according to analysts. Shares gained 0.75 percent, closing at $80.96.Analysts at MKM Partners began coverage of Hilton Worldwide (NYSE: HLT) with a Hold rating. The analyst noted that the company's PE of 13.8x fiscal 2015 estimates is among the highest in the industry. Shares are therefore fairly priced with a balanced risk/reward. Shares gained 2.95 percent, closing at $22.14.Analysts at Credit Suisse downgraded Lululemon Athletica (NASDAQ: LULU) to Neutral from Outperform with a revised price target of $59, down from a previous $78. Shares hit new 52 week lows of $58.84 before closing the day at $59.20, down 1.97 percent.Analysts at Bank of America reiterated a Buy rating on GameStop Corp (NYSE: GME) with a $59 price target. The analyst noted that the company has a “choppy” quarter but will see an improved environment as strength in console sales showing no signs of slowing down. Shares gained 3.66 percent, closing at $47.28.Analysts at Raymond James upgraded The Home Depot, Inc. (NYSE: HD) to Outperform from Market Perform based on positive comments stemming from the company's recent Investor Day Presentation which included margin upside for 2014 and the company toying with same day delivery. Shares gained 0.60 percent, closing at $79.00.Analysts at Cowen upgraded United States Steel Corp (NYSE: X) and ArcelorMittal (NYSE: MT) to Outperform from Market Perform. The two largest steelmakers based on an accelerating economy in Europe and the U.S. which should increase demand for steel products. Shares of U.S. Steel gained 3.06 percent, closing at $27.32 while ArcelorMittal gained 0.67 percent, closing at $16.46.Brixmor Property Group Inc. Com (NYSE: BRX) was initiated with a Buy rating and $23 price target at Deutsche Bank. The analyst noted that the company can deliver above average earnings growth via occupancy gains, improving rents, and select redevelopment opportunities. Shares gained 1.00 percent, closing at $20.10.According to a Bloomberg report, Google Inc. (NASDAQ: GOOG) is thinking about designing its own server processors using technology from ARM Holdings plc (NASDAQ: ARMH) putting further pressure on Intel Corporation (NASDAQ: INTC) Google lost 0.85 percent, closing at $1,060.82 while ARM Holdings gained 2.64 percent, closing at $48.90.The Boeing Company (NYSE: BA) noted that “talks are over” with the labour union over future construction of the 777X plane. The company said that it has “no plans” to return to a negotiating table and has received bids from 22 states to construct the 777X. Shares gained 0.67 percent, closing at $133.85.Las Vegas Sands Corp. (NYSE: LVS) has pulled the plug on its $35 billion casino project in Spain. The company will further explore the Asian market. Shares gained 0.49 percent, closing at $76.55.Shares of OpenTable, Inc. (NASDAQ: OPEN) traded as low as $74.65 this morning following news reports that Apple (NASDAQ: AAPL) has filed for a patent application for an advanced restaurant reservation system. The service could potentially compete against OpenTable. Shares of OpenTable traded as low as $74.65 before closing the day at $76.33, down 3.40 percent. Apple lost 1.09 percent, closing at $554.43.Honeywell International Inc. (NYSE: HON) plans to buy back $5 billion of shares. The company bought back $3 billion of shares in 2011. Shares gained 0.37 percent, closing at $86.61.Shares of SodaStream International Ltd. (NASDAQ: SODA) declined in heavy volume this morning amid rumors that a major institution is selling their shares following a 300 percent appreciation in share price since the company's IPO. Shares traded as low as $48.80 before closing at $51.22, down 1.29 percent.McDonalds Corp. (NYSE: MCD) is testing a new mobile app in hopes of reversing its previous struggles. The app will include special offers and coupons. Shares gained 0.36 percent, closing at $94.44.According to several reports, Charter Communications, Inc. (NASDAQ: CHTR) is set to make a $140 per share bid for Time Warner Cable Inc. (NYSE: TWC) Bloomberg reported that Comcast Corporation (NASDAQ: CMCSA) and Cox Communications will not be part of Charter's bid.QUALCOMM Incorporated (NASDAQ: QCOM) named its COO Steve Mollenkopf as the company's next CEO effective in March. Mollenkopf's name began to surface recently as a candidate to replace Steve Ballmer. Shares lost 0.22 percent, closing at $72.57.DIRECTV (NASDAQ: DTV) is set to renew its rights deal with the National Football League for its NFL Sunday Ticket package of games. Shares lost 0.58 percent, closing at $66.63.The Coca-Cola Company (NYSE: KO) announced a major reorganization of its Americas business. The company will split in to Coca-Cola North America and Coca-Cola Refreshments. Shares gained 0.05 percent, closing at $39.23.Winners of NoteShares of T-Mobile US, Inc. (NYSE: TMUS) surged in late afternoon after reports surfaced that Sprint Corp (NYSE: S) is mulling a bid for T-Mobile.Analysts at RBC Capital Markets reiterated a Buy rating on Twitter, Inc. (NYSE: TWTR) while upping the price target to $60 from $33. The analyst noted that 40 gpercent of advertisers reported improving ROI and have increased their marketing spend on the social media platform. 59 percent of respondents plan to increase their ad spend over the next year. Shares reached new all time highs of $59.40 before closing the day at $59.15, up 6.90 percent.Related: Twitter Quickly Reverses Course on Controversial Privacy ChangeShares of Adobe Systems (NASDAQ: ADBE) hit historical all time highs as its Creative Cloud subscriber growth impressed investors. The company added 402,000 subscribers for Creative Cloud, above its previous forecast issued in September which forecasted subscriber growth of 331,000. Shares traded as high as $61.09 before closing at $60.89, up 12.78 percent.ARC Group Worldwide, Inc. (NASDAQ: ARCW) announced that the company has formed a 3D Material Technologies division. Analysts at Brean Capital initiated coverage on the company on Wednesday with a Buy rating and $25 price target issued a price target raise in the $45 to $50 range following today's announcement. Shares gained 12.86 percent, closing at $26.86.Centene Corp (NYSE: CNC) issued forward looking guidance today. The company sees its 2014 EPS in a $3.50 to $3.80 range compared to the consensus of $3.61. The company sees next year's revenue in a $13.5 billion to $14 billion range compared to the consensus of $13.77 billion. Shares gained 6.12 percent, closing at $57.58.Electronic Arts Inc (NYSE: EA) flagship game Battlefield 4 came in at number two on NPD's bests selling games list despite recent well publicized bugs and issues. Shares gained 5.96 percent, closing at $22.22.Decliners of NoteAnadarko Petroleum Corporation (NYSE: APC) was downgraded with three separate research firms following yesterday's after market ruling against the company in the Tronox litigation. Damages could range between $5 billion and more than $14 billion. Anadarko and its Kerr-McGee unit are set to appeal the ruling. JPMorgan Chase & Co. downgraded shares to Underweight with a $77 price target, while Credit Suisse views $65 to $70 as a potential floor level valuation. Jefferies took on a bullish stance noting that the company could increase its dividend and share buybacks to restore confidence. The analyst maintained a Buy rating and $111 price target. Shares traded as low as $73.60 before closing at $78.30, down 6.42 percent.Insys Therapeutics, Inc. (NASDAQ: INSY) received a subpoena from the Department of Health and Human Services related to an investigation of potential violations involving HHS programs. Shares lost 15.63 percent, closing at $38.06.Quote of the Day"[I]t marks an important moment of bipartisan cooperation and shows Washington can and should stop governing by crisis and both sides can work together to get things done." - A White House statement following last night's budget deal.Posted-In: 3D Material Technologies Division 3D printers 3D Printers analysts adobe systems Amazon Amazon Prime anadarko petroleum ARC Group Worldwide Battlefield 4 Boeing 777X Brixmor Property Groups Budget agreement Centene Group 2014 forecast Charter bid for Time Warner Charter Communication Christine Day Coca-Cola North America Coca-Cola Refreshments Coca-Cola reorganization Creative Cloud EA EuroVegas Federal Reserve meeting fedex gamestop Goldman Sachs Greenback 2014 Hilton Worldwide Home Furnishing India inflation Insys Therapeutics ISI Group Japanese Industrial Production Kerr-McGee Las Vegas Sands Spain lululemon MKM Partners November Producer Price Index online ad spending PS4 Qualcomm CEO Raymond James retailers SodaStream Sprint Sprint offer for T-Mobile Steelmakers upgrade Stephens Steve Mollenkopf T-Mobile U.S Thomas Stolper time warner cable Tronox Tronox litigation twitter U.S dollar U.S. House U.S. Senate Video Game Console Sale Xbox OneNews After-Hours Center Best of Benzinga(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Still More Room for Disappointment in Lululemon

  Lululemon Athletica Inc. (NASDAQ: LULU) issued a weak fourth quarter guidance and cut its full year guidance on Thursday, after announcing its third quarter results.The company expects its EPS to come in at a $0.78 to $0.80 range, on revenue of $535 million to $540 million. Analysts were expecting earnings of $0.84 on revenues of $572 million.The stock plunged more than 10 percent on Thursday and continued their slide on Friday.According to Barron's, bargain hunting investors need to exercise caution, as “things are looking especially sour for Lululemon Athletica.”Related: Laurent Potdevin To Replace Christine Day As CEO of Lululemon“You don't want to be investing in a retailer still valued for robust growth when its financial results are telling you a story that growth is likely to continue to slow 12-months forward,” Brian Sozzie, chief equities strategist at Belus Capital Advisors, told Barron's.Lululemon isn't facing the same macro issues that many other retails are dealing with. “Lululemon is struggling to recover from a series of missteps and public relations snafus that depressed profit and damaged the company's once stellar reputation,” Barron's wrote.Under outgoing CEO Christine Day, the Vancouver, Canada based company earned a strong reputation and cult-like following -- that convinced customers to buy its yoga related products at a cost premium compared to its competitors.But, in a rather public debacle, the company recalled a popular line of yoga pants that were see-through. The already well-publicized blunder took a turn for the worse when the company's founde,r Chip Wilson suggested the problems are not production related, but rather the customer's fault. To help clean up the company is incoming CEO Laurent Potdevin -- who Barron's characterized as an “operations guy” -- which “should prove useful if Lululemon is to transition into a larger, international growth story.”Barron's views are similarly shared with analysts at Credit Suisse AG (NYSE: CS), who downgraded shares to Neutral from Outperform, while lowering the price target to $59 from a previous $78.Posted-In: Barron's Barron's Lululemon Belus Capital Advisors Brian Sozzie Christine Day Laurent Potdevin Lululemon Earnings Lululemon guidanceEarnings News Barron's Analyst Ratings Media Interview Press Releases Best of Benzinga(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Urstadt Biddle Properties Inc. Announces Increase in Quarterly Dividend to $0.2525 per Share From $0.25

 At their regular meeting yesterday, the Directors of Urstadt Biddle Properties Inc. (NYSE: UBA) approved an increase in the quarterly dividend rate declared for its Class A Common stock. The quarterly dividend rate declared for the Class A Common stock was increased to $0.2525 per share, which represents an annualized increase of $0.01 per share for the Class A Common shares. The Board of Directors declared a quarterly dividend for the Common shares of $0.225 per share, unchanged from the prior year. The $0.01 increase on the Class A Common stock dividend represents the twentieth consecutive year that the company has increased total dividends to its shareholders. The Class A Common and Common dividends are payable January 17, 2014 to stockholders of record on January 3, 2014. The dividends declared represent the 176th consecutive quarterly dividend on common shares declared since the Company began operating in 1969.The Directors of the company also declared the regular quarterly dividends on the Company's Series D Preferred Stock and Series F Preferred Stock. The dividends were declared in the amount of $0.46875 for each share of Series D Preferred Stock and $0.4453125 for each share of Series F Preferred Stock. The dividends are payable January 31, 2014 to stockholders of record on January 17, 2014.Urstadt Biddle Properties Inc. is a self-administered equity real estate investment trust which owns or has equity interests in 66 properties containing approximately 5.1 million square feet of space. Listed on the New York Stock Exchange since 1970, it provides investors with a means of participating in ownership of income-producing properties. It has paid 176 consecutive quarters of uninterrupted dividends to its shareholders since its inception and has raised total dividends to its shareholders for the last 20 consecutive years.Posted-In: News Dividends(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Benzinga Weekly Preview: Markets Anxiously Await Fed Meeting

   Next week the US Federal Reserve will be in the spotlight as investors anxiously wait to see whether or not the US central bank will begin to taper its bond buying plan. Recent jobs reports coupled with Washington’s bipartisan budget deal have both supported the Fed’s case to taper sooner rather than later. With that said, many are skeptical about a taper as housing data has been lack luster and the Fed may be hesitant to cut back at the end of the year.Key Earnings ReportsNext week, investors will be waiting for several key earnings reports including Oracle Corporation (NASDAQ: ORCL), Nike, Inc. (NYSE: NKE), BlackBerry (NASDAQ: BBRY), Rite Aid Corporation (NYSE: RAD), and FedEx Corporation (NYSE: FDX).Oracle CorporationOracle is expected to release second quarter EPS of $0.67 on revenue of $9.8 billion, compared to last year’s EPS of $0.64 on revenue of $9.11 billion.The analyst team at BMO has Oracle with an Outperform rating with a $42.00 target price and said the company is well positioned to continue growing and gaining market share.“Oracle, as a leading provider of database, middleware, and applications solutions, in our view, is positioned for continued growth and market share gains through leveraging its installed base (cross-sell/up-sell), favorable product refresh cycles, and surrounding the competition in customer environments. We see multiple company-specific drivers: increasing specialized sales force (+3,000), traction of engineered systems and pull-through of related software, and an apps business that is primed for long-term growth. Oracle also appears positioned for continued margin expansion through prudent spending and cost economies of scale in both its core and Sun business.”On December 12, Morgan Stanley has Oracle with an Equal-weight rating, saying the company lacked any major catalysts for growth.“ORCL now trades near our price target and, in our view, lacks an incremental catalyst to drive the multiple higher. After taking a fresh look at the four key debates on apps, data mgmt and hardware and capital returns that we laid out six months ago, we are hard-pressed to find conviction in further upside to our ests/multiple assumptions over the next year. In particular, our fourth deep-dive customer survey on Fusion Apps indicates momentum is continuing to weaken as competitive drums beat louder, while Engineered Systems growth has faded more rapidly than we expected. Net, until we see signs of product and sales investments yielding stronger returns, ORCL looks fairly valued at ~12x NTM P/E, in line with EPS growth and approaching long-term averages.”Also on December 12, RBC Capital Markets has Oracle with a Sector Perform rating with a $35.00 price target. The analysts at RBC said its reduced rating was attributed to Oracle’s share price nearing the firm’s Price target.“ORCL now trades near our price target and, in our view, lacks an incremental catalyst to drive the multiple higher. After taking a fresh look at the four key debates on apps, data mgmt and hardware and capital returns that we laid out six months ago, we are hard-pressed to find conviction in further upside to our ests/multiple assumptions over the next year. In particular, our fourth deep-dive customer survey on Fusion Apps indicates momentum is continuing to weaken as competitive drums beat louder, while Engineered Systems growth has faded more rapidly than we expected. Net, until we see signs of product and sales investments yielding stronger returns, ORCL looks fairly valued at ~12x NTM P/E, in line with EPS growth and approaching long-term averages.”Nike, Inc.Nike is expected to release second quarter EPS of $0.58 on revenue of $6.44 billion, compared to last year’s EPS of $0.57 on revenue of $5.96 billion.In mid-September, Piper Jaffray has Nike with a Neutral rating with a $71.00 price target, saying the company’s outlook in the near term was more positive than its competitors.“We believe the next several weeks potentially offer a compelling trade opportunity for NKE shares on the long side. The following events over the next four weeks could all be positive catalysts for NKE shares: Dick's Sporting Goods analyst day on September 18th, Nike's FQ1 earnings in late September, Nike's analyst day on October 9 and NKE shares being added to the DJIA on September 23. Furthermore, we believe product innovation such as Flyknit, mildly improving macroeconomic conditions in China and several global sporting events in 2014 provide a favorable backdrop. Lastly, NKE's earnings multiple relative to UA is approaching its historic low, which has typically been a good indicator of NKE's relative outperformance. We have raised our 12-month price target from $64 to $71, but are maintaining our Neutral rating given valuation.”JP Morgan has Nike with an Overweight rating with an $80.00 price target on October 1. The analysts at JP Morgan noted several risks to Nike’s success, including the current employment figures in the US, which could stifle consumer spending.“The economic climate, particularly the employment picture, can affect consumer spending and the department store industry. A greater than expected downturn in household spending could cause sales trends to decelerate below our current assumptions, rendering our estimates too high. Conversely, an improvement in the economy could render our estimates too low.”BlackBerryBlackBerry is expected to report a loss of $0.43 per share on revenue of $1.58 billion, compared to last year’s loss of $0.22 on revenue of $2.73 billion.CIBC has BlackBerry with a Sector Underperform rating with a $5.00 price target on November 4. The analysts at CIBC said that although BlackBerry’s balance sheet is improving, the company faces a long road to recovery.“BB's balance sheet is now in good shape. Pro-forma cash (convert & restructuring) is $3.1B or ~$5/share. BB's survival was an issue for many enterprises who have watched the downward spiral. Today's cash up should alleviate the financial concerns, but competitive ones remain. BB's long-term strategy is a return to focus to the enterprise market. There are many issues with BB, but the largest one is BYOD led by iPhone and Samsung's Galaxy. Today it's not clear what a realistic BB response is. Establishing BB's competitive edge here is the largest unknown. We lower our rating to SU and PT to $5 from $12. Our prior thesis was the shares could only be bought for this sale process that has now failed. Current fundamentals are quite weak (Q3 market share 1% vs. 2.7% Q2, 4.3% Q3 LY) and yield a lower price, hence our downgrade to SU.”On the 15 of November, Macquarie also has BlackBerry with an Underperform rating with a price target of $5.50. The analysts at Macquarie noted that although the company’s CEO has been praised, they found several red flags upon closer inspection.“While we have heard very good things about Mr. Chen from his days at Sybase, we are concerned that he is not relocating to Waterloo and that he is not the permanent CEO. Furthermore, a review of the filings suggests that Mr. Chen appears to be incentivized to sell the company as one entity, which would accelerate his vesting on 13mm RSUs upon a change in control, with a further $6mm cash termination payment. We believe investors would prefer Mr. Chen's long-term compensation package to be tied to profitability thresholds and/or share price performance relative to the market or peers.”On the November 5, Societe Generale was more positive about BlackBerry and has a Hold rating with a $7.00 price target. The firm’s optimism came from news that BlackBerry had decided not to sell itself.“Blackberry announced yesterday that it has abandoned plans to sell itself to an investor consortium (which includes its largest shareholder Fairfax) for $9 per share. Instead, a consortium of investors (again including Fairfax) will invest $1bn in Blackberry in the form of convertible debentures. The investment should be completed within the next two weeks. The debentures will have a coupon of 6% and will be convertible into shares at $10 per share. The debentures have a term of seven years. Assuming all $1bn of the debentures are converted, the debenture holders would own 16% of the enlarged share capital. In addition to the financial transaction, it was also announced that the current CEO will resign as CEO from the board once the deal has closed. Peter Chen, the ex-CEO of Sybase, will join the board as the Interim CEO pending the completion of a search for a new CEO.”Rite Aid CorporationRite Aid is expected to release third quarter EPS of $0.04 on revenue of $6.29 billion, compared to last year’s EPS of $0.07 on revenue of $6.24 billion.BTIG has Rite Aid with a Buy rating with a $6.00 price target on October 3. The analyst team at BTIG saw a bright long term future for Rite Aid based on changes to healthcare policies in the US.“We have reason to believe that results will improve from here over the longer term. While second half guidance was strong, it already incorporates the threat of increased reimbursement pressures and the weakness in new generics. What the guidance omits is any positive impact in the second half from the launch of the exchanges associated with the Affordable Care Act – even though that guidance already incorporates the cost of paying for more than two thousand consultants working in RAD’s locations to help existing and prospective RAD customers to sign up for ACA coverage.”On October 7, Jefferies has Rite Aid with a Hold rating with a $5.30 price target, noting that although the company has made progress, it faces several headwinds in the future.“Rite Aid has made progress in its turnaround, but we see declining EBITDA in the near-term as the company faces a fading generic drug wave, and some attrition from the Express Scripts customer wins from last year. Given Rite Aid's financial leverage, and its 30-40% lower store productivity vs. CVS and WAG, we believe the current EV/EBITDA discount vs. these peers is justified.”FedEx CorporationFedEx is expected to release second quarter EPS of $1.62 on revenue of $11. 43 billion, compared to last year’s EPS of $1.39 on revenue of $11.11 billion.JP Morgan revised its estimate for FedEx from Neutral to Overweight with a price target of $154.00 on October 22. The analysts at JP Morgan noted that FedEx’s buyback announcement instilled some confidence in the company.“What has changed to drive our upgrade to OW? We have been cautious on FDX for the past four months due primarily to concerns regarding the headwind from trade down and excess international airfreight capacity. While we still have concerns about trade down, we now believe that the combination of FDX’s Asia / U.S. air capacity reductions and its initial steps to flow IE into commercial lift provide the ability for FDX to absorb trade down pressures. We also read FDX’s large and uncharacteristic buyback announcement last week as indicating they are being aggressive and they are willing to change to drive improvement.”Citi’s analysts were also optimistic and has FedEx with a Buy rating with a price target of $170.00 on December 10.“We believe further upside in FedEx shares remains, as the current investor base appears to be playing for a meaningful improvement in profitability, led by cost efforts underway at the company's Express segment. Sentiment is firming around FedEx's ability to produce profit improvement and coupled with accretion from the buyback and help from improving volumes, $10 of earnings power should enter the discussion for F15. We are increasing our target to $170 and reiterate our Buy”Economic ReleasesAlthough the Fed will be on everyone’s mind next week, European PMI data is also due out and will be closely watched. Last month’s figures were slightly weaker, but still indicated growth. Most are expecting to see similar figures out this week. France’s PMI last month showed a disappointing contraction and if this month’s figures follow the same trend, it will signal that last month’s data was not a fluke and instead that the nation has fallen off track.Daily ScheduleMondayEarnings Releases Expected: No notable releases expectedEconomic Releases Expected:  US industrial production, Italian trade balance, eurozone manufacturing and services PMITuesdayEarnings Expected From: Jabil Circuit, Inc. (NASDAQ: CSPI), Verifone Systems, Inc. (NYSE: PAY)Economic Releases Expected: Japanese trade balance, New Zealand current account, US current account, US CPIWednesdayEarnings Expected From: General Mills, Inc. (NYSE: GIS), Lennar Corporation (NYSE: LEN), FedEx Corporation (NYSE: FDX), Oracle Corporation (NASDAQ: ORCL)Economic Releases Expected: US FOMC meeting announcement, US housing starts, US building permits, British unemployment rate, Indian interest rate decision.ThursdayEarnings Expected From: Accenture plc. (NYSE: ACN), Pier 1 Imports, Inc. (NYSE: PIR), ConAgra Foods, Inc. (NYSE: CAG), Rite Aid Corporation (NYSE: RAD), Nike, Inc. (NYSE: NKE), Red Hat, Inc. (NYSE: RHT)Economic Releases Expected: British consumer confidence, US existing home sales, British retail sales, British mortgage approvals, eurozone current account, Swiss trade balance.FridayEarnings Expected From:  BlackBerry (NASDAQ: BBRY), CarMax Inc. (NYSE: KMX), Walgreen Co. (NYSE: WAG), The Finish Line, Inc. (NASDAQ: FINL)Economic Releases Expected:  eurozone consumer confidence, US GDP, US consumer spending, Italian trade balancePosted-In: Federal ReserveNews Previews Economics Federal Reserve Pre-Market Outlook Markets Trading Ideas Best of Benzinga(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Why InterCloud Systems Was Up More than 20 Percent Friday

  If you owned shares of InterCloud Systems (NASDAQ: ICLD) prior to Friday, you’re having a great week.The stock was up as much as 35 percent and has settled in with gains of about 20 percent in Friday trading.The reason for the move is a press release from the company Friday morning announcing the acquisition of Integration Partners-NY Corporation. (IPC-NY) The company will finance the acquisition through $11.62 million in convertible debentures, which mature in June of 2015.InterCloud is in the technology space that investors love: The cloud. The $72 million company provides design, installation, and maintenance of cloud services, along with IT consultation, and voice, data and optical services to end users.It’s acquisition of IPC-NY will add $25 million in gross revenue and income of $3.5 million in 2013, according to the release.Related: The Market Noise Is Just That: NoiseIPC-NY is an IT firm that offers similar services as InterCloud. According to the company website, it provides everything from network management to the installation of green data centers.InterCloud CEO Mark Munro said, "We are excited about the synergies this acquisition brings to InterCloud and its immediate accretive earnings effect. IPC-NY is a growing business with a seasoned and successful management team.”But is today’s news a reason to jump into InterCloud?While acquisitions are normally a means of growth for larger companies, InterCloud acquired a string of companies in the past two years. Prior to today’s news it announced that it had acquired AW Solutions for $5.2 million in April of this year.In 2012, the company made two acquisitions—more than investors would normally expect from a small cap. name.Until October 31, the stock traded on the OTCQB. Investors are often hesitant to invest in small speculative companies listed outside of the major exchanges because of liquidity risk and a lack of coverage. InterCloud’s October 31 IPO as a NASDAQ stock added credibility, further company coverage,  and a whole lot of liquidity.Before the stock listed on NASDAQ, it traded an average of 10,000 shares daily. Since it’s listing, nearly one million shares trade daily with today’s volume already topping 2.8 million as of midday.InterCloud IPOed at $4 per share—well below the expected range of $5 to $7. Post-IPO, the stock fell to $2.20 but after a better than expected earnings announcement last month, the stock rocketed up to a high of $14.58 only to settle in around $9 per share after profit taking—a price point where investors seem to have felt comfortable valuing it.Friday’s announcement added 20 percent but with a stock as volatile as InterCloud, committing new money may not be wise until any profit taking is complete and investors reprice the stock.Many of its metrics are impressive headline numbers. According to its third-quarter release, revenue was up 448 percent year over year but some of it stems from the close of 2012 acquisitions.A Seeking Alpha article pointed out that InterCloud’s strategy with acquisitions is to gain a more international presence but along with acquisitions often comes more debt. For that reason, don’t look at triple-digit moves to the upside and decide to pour money into any name.How is the company handling the debt that comes with acquisitions? What is CEO Mark Munro’s plan for differentiating the company from the many other cloud providers? This information is in the earnings statements and data at InterCloud’s investor page.All of the big names that capture the news headlines once started as small companies. Finding the up-and-comers is worth a small allocation of your portfolio dollars.Disclosure: At the time of this writing, Tim Parker had no position in the company mentioned and has no plans to purchase in the near future.Posted-In: Integration Partners InterCloudNews M&A Best of Benzinga(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

FDA Approves Gilead's Once-Daily Single Tablet HIV-1 Regimen Complera® for Patients Switching from a Stable Regimen; Also Approved by European Comission

 Gilead Sciences (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the single tablet HIV-1 regimen Complera^® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.“Complera is an effective single-pill therapy with a demonstrated safety profile, and has rapidly become an important option for appropriate HIV patients who are initiating antiretroviral treatment,” said Calvin J. Cohen, MD, M.Sc., Research Director, Community Research Initiative of New England and an investigator on clinical trials of Complera. “The data supporting today's approval demonstrate Complera has the potential to help a broader range of HIV-infected patients who have achieved virologic control on another regimen.”Complera combines a complete course of three antiretroviral medications into a single, once-daily tablet. The product contains Gilead's Truvada^®, which itself is a fixed-dose combination of two HIV medicines, and Janssen R&D Ireland's rilpivirine (marketed as Edurant^®). Patients switching to Complera should have no history of virologic failure, have suppressed viral load for at least six months, be on their first or second antiretroviral regimen, and have no current or past history of resistance to Complera components. The efficacy of Complera was established in patients who were virologically suppressed (HIV RNA <50 copies/mL) on a stable ritonavir-boosted protease inhibitor-containing regimen.Today's approval is supported by clinical data from the Phase 3 SPIRIT (Study 106) clinical trial. In this randomized, open-label study, virologically suppressed patients who were taking multi-tablet HIV therapy containing a ritonavir-boosted protease inhibitor (PI) either switched to Complera or remained on their PI-based regimen. The study found that, after 48 weeks of treatment with Complera, 89 percent (n=283/317) of switch patients had viral load less than 50 copies/mL, compared to 90 percent (143/159) of patients who remained on a PI-regimen for 24 weeks. Complera was well tolerated in SPIRIT and there were few treatment discontinuations due to adverse events. The most common side effects in previous clinical studies of Complera were headache, depressive disorders and insomnia (2 percent for all). No new adverse reactions were identified in SPIRIT, but the frequency of adverse reactions increased from 2 percent to 2.4 percent. Complera has a labeled Boxed Warning on the risks of lactic acidosis/severe hepatotoxicity with steatosis and acute exacerbation of hepatitis B; see below for Important Safety Information.Marketed as Eviplera^® (emtricitabine/rilpivirine/tenofovir disoproxil (as fumarate)) in the European Union, the regimen also was recently granted European regulatory approval for any HIV-infected adult patients without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with a viral load = 100,000 HIV-1 RNA copies/mL.Important Safety Information about CompleraBOXED WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS BLactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate (tenofovir DF), a component of COMPLERA, in combination with other antiretrovirals.COMPLERA is not approved for the treatment of chronic hepatitis B virus (HBV) infection and the safety and efficacy of COMPLERA have not been established in patients coinfected with HBV and HIV-1. Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HBV and HIV-1 and have discontinued emtricitabine or tenofovir DF, which are components of COMPLERA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue COMPLERA. If appropriate, initiation of anti-hepatitis B therapy may be warranted.CONTRAINDICATIONS* Coadministration: COMPLERA should not be coadministered with drugs that induce CYP3A or increase gastric pH as this may lead to loss of virologic response and possible resistance to COMPLERA. Use of the following drugs with COMPLERA is contraindicated: carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, proton pump inhibitors (e.g., esomeprazole, lansoprazole, dexlansoprazole, omeprazole, pantoprazole, rabeprazole), systemic dexamethasone (>1 dose) and St. John's wort.WARNINGS AND PRECAUTIONS* New onset or worsening renal impairment: Cases of acute renal failure and Fanconi syndrome have been reported with the use of tenofovir DF. In all patients, assess estimated creatinine clearance (CrCl) prior to initiating and during therapy. In patients at risk for renal dysfunction, additionally monitor serum phosphorus, urine glucose, and urine protein. Do not administer COMPLERA in patients with CrCl <50 mL/min. Avoid concurrent or recent use with a nephrotoxic agent. Cases of acute renal failure, some requiring hospitalization and renal replacement therapy, have been reported after initiation of high dose or multiple NSAIDs in patients with risk factors for renal dysfunction; consider alternatives to NSAIDs in these patients. Persistent or worsening bone pain, pain in extremities, fractures and/or muscular pain or weakness may be manifestations of proximal renal tubulopathy and should prompt an evaluation of renal function.* Drug interactions: Use COMPLERA with caution when given with drugs that may reduce the exposure of rilpivirine or when coadministered with a drug with known risk of Torsades de Pointes. Supratherapeutic doses of rilpivirine have been shown to prolong the QTc interval of the electrocardiogram (ECG) in healthy subjects.* Depressive disorders: The incidence of depressive disorders (depressed mood, depression, dysphoria, major depression, mood altered, negative thoughts, suicide attempt, suicidal ideation) reported in clinical trials (N=686) was 9% (most were mild or moderate in severity); and Grades 3 and 4 depressive disorders (regardless of causality) was 1%. Suicidal ideation was reported in 4 subjects and suicide attempt was reported in 2 subjects. Patients with severe depressive symptoms should seek immediate medical evaluation and the risks of continued therapy should be determined.* Hepatotoxicity: Hepatic adverse events have been reported, including cases of hepatic toxicity in patients without pre-existing hepatic disease or other identifiable risk factors. Patients with underlying hepatitis B or C, or those with marked elevations in liver-associated tests may be at increased risk. Appropriate laboratory testing and monitoring before and during therapy is recommended in patients with underlying hepatic disease or in patients with marked elevations in liver-associated tests prior to treatment initiation; consider testing and monitoring in patients without pre-existing hepatic dysfunction or other risk factors.* Bone effects: Decreases in bone mineral density (BMD) and mineralization defects, including osteomalacia, have been seen in patients treated with tenofovir DF. Consider monitoring BMD in patients with a history of pathologic fracture or risk factors for bone loss. In patients at risk of renal dysfunction who present with persistent or worsening bone or muscle symptoms, hypophosphatemia and osteomalacia secondary to proximal renal tubulopathy should be considered.* Other antiretrovirals: COMPLERA is a complete regimen for the treatment of HIV-1 infection. Do not coadminister with other antiretrovirals including products containing any of the same active components, products containing lamivudine, or with adefovir dipivoxil.* Fat redistribution and accumulation has been observed in patients receiving ARV therapy.* Immune reconstitution syndrome, including the occurrence of autoimmune disorders with variable times to onset, has been reported.ADVERSE REACTIONS* In adults with no ARV treatment history: Common adverse reactions reported in clinical studies (incidence =2%, Grades 2-4) were depressive disorders (2%), insomnia (2%) and headache (2%). * In virologically suppressed adults: No new types of adverse reactions to COMPLERA were identified in stable, virologically suppressed patients switching to COMPLERA; however, the frequency of adverse reactions increased by 20%.DRUG INTERACTIONS* CYP3A inducers: Drugs that induce CYP3A may decrease rilpivirine plasma concentrations which may lead to loss of virologic response and possible resistance to COMPLERA. * CYP3A inhibitors: Drugs that inhibit CYP3A may increase rilpivirine plasma concentrations. * Drugs increasing gastric pH may significantly decrease rilpivirine plasma concentrations and lead to loss of virologic response and possible resistance to COMPLERA.* Use of proton pump inhibitors with COMPLERA is contraindicated. * Antacids should be administered =2 hours before or =4 hours after COMPLERA. * H[2 ]receptor antagonists should be administered =12 hours before or =4 hours after COMPLERA.* Drugs affecting renal function: Coadministration of COMPLERA with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of emtricitabine and tenofovir. * Prescribing information: Consult the full Prescribing Information for COMPLERA for more information on potentially significant drug interactions, including clinical comments.Pregnancy and Breastfeeding* Pregnancy Category B: There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if potential benefits justifies the potential risk. An Antiretroviral Pregnancy Registry has been established. * Breastfeeding: Emtricitabine and tenofovir have been detected in human milk. Because of both the potential for HIV transmission and the potential for serious adverse reactions in nursing infants, mothers should be instructed not to breastfeed.DOSAGE AND ADMINISTRATIONAdults: One tablet taken orally once daily with food.Renal Impairment: Do not use in patients requiring dose adjustment or patients with estimated CrCl <50 mL/min.About Gilead SciencesGilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North and South America, Europe and Asia Pacific.Forward-Looking StatementThis press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including the risk that healthcare providers in the United States and European Union may not see advantages of switching virologically suppressed HIV patients to Complera/Eviplera and may therefore be reluctant to prescribe the product. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements..U.S. full prescribing information for Complera and Truvada, including BOXED WARNING for both products, is available at www.Gilead.com.EU Summaries of Product Characteristics for Eviplera and Truvada are available at http://www.ema.europa.eu.Complera, Eviplera, and Truvada are registered trademarks of Gilead Sciences, Inc., or its related companies.Edurant is a registered trademark of Janssen R&D Ireland.For more information on Gilead Sciences, please visit the company's website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.Posted-In: News FDA(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Alexion Provides Update on Recall of Two Soliris Lots; Says No Effect on FY14 Outlook

 Alexion Pharmaceuticals (NASDAQ: ALXN) today is providing further information regarding a previously communicated voluntary recall of two lots of Soliris® (eculizumab) Concentrated Solution for Intravenous Infusion. As stated on Nov. 12, 2013, the two lots were found to contain visible particles. At that time, Alexion provided instructions to return any unused vials of Soliris from these two lots at the distributor level. Alexion is now providing the same instructions at the hospital/user level.The administration of particulate, if present in a parenteral drug, poses a potential safety risk to patients in two general areas: immunogenicity and thromboembolic events. Particulates could cause blockage of flow of blood in vessels, which could be life-threatening. To date, there have been no product complaints of particulates, or identifiable safety concerns attributed to the product consumed from the affected lots. As previously stated, Alexion does not anticipate any interruption to patient supply of Soliris.The product is approved as a treatment for patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, two ultra-rare disorders. Alexion and its distributors typically ship Soliris to healthcare providers in small quantities, which are timed to individual patient infusions, with the product being consumed before more is shipped. As product was last shipped on Nov. 1, 2013, Alexion believes there is little, if any, inventory currently being held at the hospital or user level.The following table lists the two affected lots, which were distributed nationwide.Expiration First Last Product     Lot     Date     Ship Date     Ship Date Soliris® (eculizumab) Oct. 11, Nov. 1, 300 mg/30 mL     10010A     Oct. 31, 2015     2013     2013Concentrated solution for intravenous infusion only     10001-1     July 31, 2014     June 4,     May 8, 2012 2013 NDC 25682-001-01As previously disclosed, Alexion believes that it has identified the filling process step that resulted in the presence of the visible particles and implemented the change necessary to correct the issue. To date, visible particles have not been observed in other lots of Soliris distributed in the U.S.Any person in possession of vials of Soliris from these lots should stop use and arrange for return of the product to Alexion immediately by calling 1-888-SOLIRIS (888-765-4747).Alexion will replace any recalled vials of Soliris. Unaffected lot numbers can continue to be used according to the instructions for use.Healthcare professionals and pharmacists with questions regarding this recall can contact Alexion at 1-888-765-4747. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.* Online: www.fda.gov/medwatch/report.htm * Regular Mail: Use postage-paid, pre-addressed Form FDA 3500 available at: www.fda.gov/MedWatch/getforms.htm. Mail to address on the pre-addressed form. * Fax: 1-800-FDA-0178This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.About AlexionAlexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition and has developed and markets Soliris® (eculizumab) as a treatment for patients with PNH and aHUS, two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. Soliris is currently approved in nearly 50 countries for the treatment of PNH, and in the United States, European Union, Japan and other countries for the treatment of aHUS. Alexion is evaluating other potential indications for Soliris in additional severe and ultra-rare disorders beyond PNH and aHUS, and is developing other highly innovative biotechnology product candidates across multiple therapeutic areas. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at: www.alexionpharma.com. Posted-In: News Guidance(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

3-D Printing is all the Rage on Wall Street

  3-D Printing is all the Rage on Wall Street | Benzinga Benzinga Benzinga Pro Marketfy Facebook Twitter LinkedIn Google+ RSS Free Streaming News Membership is FreeWhat are you waiting for? Sign up now! Username: Username available!Username taken! Email: Email available!Email taken! Password: Leave blank: already have an account?User LoginI bet you can't wait to get back in here... Username or email: Password: need an account?Forgot password? Contribute Login Sign up Benzinga - Feed Your Mind. HomeBest of BenzingaCareersAboutContact UsPartnersNewsEarningsGuidanceDividendsM&ABuybacksLegalManagementRetail SalesOfferingsIPOsInsider TradesBiotech/FDAMarketsPre-MarketAfter HoursMoversForexCommoditiesOptionsBondsFuturesGlobal EconomicsPreviewsReviewsRatingsAnalyst ColorDowngradesUpgradesInitiationsPrice TargetIdeasLong IdeasShort IdeasTechnicalsFrom The PressJim CramerRumorsETFsTechStart-UpsSmall-CapTrading Strategies & Education Long IdeasShort IdeasTechnicalsFrom The PressJim CramerRumorsETFs Market Overview TickersArticlesKeywordsSearch by keyword...googlecse 3-D Printing is all the Rage on Wall Street Daniel Jennings, Benzinga Staff Writer December 13, 2013 4:04 PM + Follow Print Email Tickers: DDD, SSYS, SSYS DDD XONE VJET, VJET, XONE Share: It looks like 3-D printing has come of age.Fantastic growth in share prices for the manufacturers of 3-D printing equipment has attracted the attention of some of Wall Street's biggest banks.Analysts at Deutsche Bank AG, Jeffries LLC, Credit Suisse Group AG, JP Morgan Chase, Piper Jaffray Cos. and Citigroup Inc. have started covering 3-D printer manufacturers, The Wall Street Journal reported. Piper Jaffray analyst Troy Jenson told the Journal 3-D printing stocks, once a sleepy universe, have suddenly taken off.Some of the hot 3-D printing stocks that analysts are following include:Stratasys (NASDAQ: SSYS), a leader in inkjet based 3-D printing. Stratasys' shares have been on a tear lately. At midday on Thursday, Stratasys was trading at $121.10 a share and it was up 1.97 percent, or $2.34 a share. So it's easy to see why analysts are interested in this company.3D Systems Corporation (NYSE: DDD), which isn't exactly a 3D printing company. Instead 3D Systems makes the advanced imaging technology used in 3D printing. Like SSYS, 3D showed incredible share growth on Thursday, rising by $2.57 or 3.32 percent a share to $80.10 at midday.The ExOne Company (NASDAQ: XONE), which specializes in machines that make metal parts for manufacturers in what is known as digital part materialization. ExOne's shares were also up on Thursday, rising 32¢ or .58 percent to $54.32 by midday.Voxeljet (NYSE: VJET), a German manufacturer of 3D printing systems that went public in August. Voxeljet's shares were up by 1.73 percent, or 64¢, on Thursday to $37.59 a share. Voxeljet's share price is also a perfect illustration of how volatile 3D printing stocks still are. On Nov. 15, its share price rose to $58.99 before taking a tumble to $33.82 on Nov. 21.3D printing might be the future of manufacturing, but Voxeljet proves that 3D printing shares are not for the faint of heart. If you don't like risk you should stay away from this sector.Posted-In: 3D 3D printers 3D Printing 3D printing industry Troy JensonLong Ideas News Short Ideas Wall Street Journal Movers & Shakers Small Cap Analysis Politics Offerings Psychology Small Cap Startups Small Business Hot Analyst Ratings Media Trading Ideas General(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.  Most Popular China Mobile Accidentally Took iPhone 5S Pre-Orders Ahead Of Official Announcement 'Streaming Only Cable Service is Coming,' Say Experts The Reason for Wednesday's Hard Fall in Stocks: 'Dangerous, But Necessary' Johnson & Johnson Shares Under Pressure For Second Day in a Row UPDATE: GE Board Approves 16% Increase in Quarterly Dividend Three Bullish Apple Data Points Related Articles (DDD + SSYS) Market Wrap For December 13: Major Indices Finish The Day Flat 3-D Printing is all the Rage on Wall Street 3D Systems Acquires Village Plastics; Terms Not Disclosed UPDATE: Jefferies Initiates Coverage on Stratasys on Market Leader Position UPDATE: Jefferies Initiates Coverage on 3D Systems on Market Leader Position Mid-Afternoon Market Update: Markets Fall as 3D Systems Rallies on Deutsche Bank Initiation Around the Web, We're Loving... Lightspeed Trading Presents: Thunder and Tubleweeds: Trading Techniques for the New Market Enviroment Pope Francis Rips 'Trickle-Down' Economics Come See How the Pro's Trade in this Exclusive Webinar Wynn, MGM, Other Casino Giants Vying For U.S. Turf What Should You Know About AMZN? Partner Network Get Benzinga's News Delivered Free Zing Talk: Daily Top Stories PreMarket Primer See More » Weekly ETF Outlook Weekly Options Outlook Daily Ratings Summary Posts by Daniel Jennings 3-D Printing is all the Rage on Wall Street Nokia Wants to Transfer Factory to Microsoft Amazon Rolling Out Grocery Delivery in More Cities MasterCard Raises Quarterly Dividend by 83%, But Some Analysts Say Hold On Post Office Expands Same-Day Delivery Test to New York Most Read Most Recent 1 China Mobile Accidentally Took iPhone 5S Pre-Orders Ahead Of Offi... 2 'Streaming Only Cable Service is Coming,' Say Experts 3 The Reason for Wednesday's Hard Fall in Stocks: 'Dangerous, But N... 4 Johnson & Johnson Shares Under Pressure For Second Day in a Row 5 UPDATE: GE Board Approves 16% Increase in Quarterly Dividend 6 Three Bullish Apple Data Points 7 AT&T CEO Says Smartphone Subsidies Must End 1 Market Wrap For December 13: Major Indices Finish The Day Flat 2 Still More Room for Disappointment in Lululemon 3 Benzinga Weekly Preview: Markets Anxiously Await Fed Meeting 4 Urstadt Biddle Properties Inc. Announces Increase in Quarterly Di... 5 FDA Approves Gilead's Once-Daily Single Tablet HIV-1 Regimen Comp... 6 Large Option Trade in Volatility, Why You Should be Paying Attention 7 3-D Printing is all the Rage on Wall Street Benzinga Professional Subscribe 7:20 PM Rage against the regulators via ForexLive 5:23 PM Starboard Reports Increased Stake in Office Depot to 8.2% 04:45 PM Market Wrap For December 13: Major Indices Finish The Day Flat 04:38 PM Still More Room for Disappointment in Lululemon 04:34 PM Benzinga Weekly Preview: Markets Anxiously Await Fed Meeting 04:33 PM Urstadt Biddle Properties Inc. Announces Increase in Quarterly Dividend to $0.2525 per Share From $0.25 04:32 PM FDA Approves Gilead's Once-Daily Single Tablet HIV-1 Regimen Complera® for Patients Switching from a Stable Regimen; Also Approved by European Comission 4:23 PM ForexLive Americas wrap: USD/CAD slumps below 1.06 via ForexLive 04:04 PM 3-D Printing is all the Rage on Wall Street 04:01 PM Alexion Provides Update on Recall of Two Soliris Lots; Says No Effect on FY14 Outlook 3:58 PM UPDATE: Dow Jones Reports Sprint Bid For T-Mobile Could Come in First Half of 2014, Could Face US Antitrust Issues 3:56 PM Sprint Working Toward a Bid for T-Mobile US -- Sources 3:53 PM Option Alert: Asiainfo Linkage Spikes Higher; 2,122 January $ 12 Contract Trade @$0.35 3:51 PM Option Alert: AerCap January $30 Call; 1,865 Contract Trade @$0.30; Currently $24.84 3:51 PM Hammerstone Hammerforum Imbalance Update: Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content. Popular ChannelsAnalyst RatingsBe Your Own BossETFsEconomicsForexHotNewsOptionsPress ReleasesStart-upsTechTools & FeaturesAffiliate ProgramBadgesFeedsNews WidgetReal Time FeedSitemapSubmit News TipsAbout BenzingaAbout UsBlogIn the NewsCareersContact UsDisclaimerPrivacy PolicySyndicationTerms and Conditions Benzinga Partners 1 (877) 440-9464 (ZING) Benzinga.com © 2013 Large Option Trade in Volatility, Why You Should be Paying Attention Alexion Provides Update on Recall of Two Soliris Lots; Says No Effect on FY14 Outlook